Newsgather

Mounjaro

Sabit25 haber11 kaynakSon güncelleme: 2 g önce

Son Haberler

Drug Repurposing: From Diabetes to Weight Loss and Beyond
Gelişiyor
Sağlık·3 g önceAI özeti

Drug Repurposing: From Diabetes to Weight Loss and Beyond

The article explores drug repurposing, highlighting GLP-1 agonists like Ozempic and Wegovy, initially for diabetes, now used for weight loss, cardiovascular health, and more. It also discusses COVID-19 treatments like dexamethasone and baricitinib, and historical examples like raloxifene, thalidomide, BCG vaccine, and Viagra, emphasizing both the benefits and potential risks of using drugs for unapproved conditions.

D
Deutsche Welle
Woman, 2 others sent to prosecutors for illegally selling diabetes drug Mounjaro
HABER
02.06.2026AI özeti

Woman, 2 others sent to prosecutors for illegally selling diabetes drug Mounjaro

Osaka Prefectural Police have referred a 35-year-old company employee and two others to prosecutors on suspicion of violating the Pharmaceuticals and Medical Devices Act by illegally selling and storing the diabetes drug Mounjaro without a license. The drug, known for its appetite-suppressing effects and marketed as a "slimming drug" on social media, has seen widespread use for diet purposes.

時事通信
3 arrested for illegal online sale of diabetes drug Mounjaro for diet purposes
HABER
02.06.2026AI özeti

3 arrested for illegal online sale of diabetes drug Mounjaro for diet purposes

Osaka police have referred three individuals (ages 22-35) from Osaka and Nara prefectures to prosecutors on suspicion of violating the Pharmaceuticals and Medical Devices Act for illegally selling the diabetes drug Mounjaro online, reportedly for diet purposes. This marks a rare nationwide case of prosecution for the personal online sale of Mounjaro, which is gaining popularity among young people for weight loss.

毎日新聞
GLP-1 ilaçları küresel yükselişte: Ozempic, Wegovy ve Mounjaro'nun etkileri
Sağlık
04.05.2026AI özeti

GLP-1 ilaçları küresel yükselişte: Ozempic, Wegovy ve Mounjaro'nun etkileri

Semaglutid içeren GLP-1 ilaçları (Ozempic, Wegovy, Mounjaro), Tip 2 diyabet ve obezite tedavisinde kullanımı artan ilaçlar. ABD'de obezite oranlarının yüksek olduğu eyaletlerde GLP-1 kullanımı da yoğunlaşıyor. En yüksek kullanım yüzde 24 ile West Virginia'da, en düşük yüzde 5 ile Hawaii'de. İlaçların aylık maliyeti 25-1.112 dolar arasında değişirken, Hindistan'da jenerik versiyonları yüzde 60'a varan indirimle satışa sunuluyor. DSÖ, uzun dönem verilerin sınırlı olduğunu vurguluyor.

A
AA Güncel